ProQR Therapeutics (PRQR) Set to Release Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) will likely be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect ProQR Therapeutics to post earnings of ($0.11) per share and revenue of $4.30 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. The firm had revenue of $10.00 million for the quarter, compared to the consensus estimate of $4.56 million. On average, analysts expect ProQR Therapeutics to post ($0.45) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

ProQR Therapeutics Stock Up 3.8%

Shares of NASDAQ:PRQR opened at $1.37 on Wednesday. ProQR Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $2.65. The business has a 50-day moving average of $1.71 and a two-hundred day moving average of $1.69.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PRQR. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Thursday, October 1st. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Chardan Capital reissued a “buy” rating and issued a $3.00 price target on shares of ProQR Therapeutics in a research report on Thursday, October 1st. Bank of America started coverage on shares of ProQR Therapeutics in a research note on Thursday, August 20th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 15th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $7.60.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA.

ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR serves the global biotechnology and pharmaceutical markets through its research, development and strategic collaborations.